Tolaney S, et al. MonarcHER: a randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of care chemotherapy in women with HR+, HER2+ advanced breast cancer. Abstract LBA23. ESMO Congress 2019, 29 sept. Barcelona, Spanje.
Significant overlevingsvoordeel fruquintinib bij refractair gemetastaseerd colorectaal carcinoom
sep 2023 | Maag-darm-leveroncologie